EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)

Pharmacokinetics and Safety of a Fixed‐Dose Combination of Alogliptin and Extended‐Release Metformin Under Fasting and/or Fed Conditions in Healthy Adults

Ji Hye Song, Jae Hoon Kim, Jang Hee Hong, Jin-Gyu Jung, Sun Young Park, Jung Sunwoo

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1532 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Ji Hye Song und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trials Center, Chungnam National University Hospital, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Metformin, Fasting, Uracil, Food-Drug Interactions. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This phase 1, randomized, open‐label, 2 × 2 crossover study evaluated the bioequivalence of fixed‐dose combination (FDC) formulations of alogliptin (ALO) and metformin extended‐release (MET XR) compared to their individual formulations and assessed the effect of food on FDC pharmacokinetics in healthy participants. The study comprised the high‐dose bioequivalence study (ALO 25 mg/MET XR 1000 mg) and the low‐dose bioequivalence study (ALO 12.5 mg/MET XR 500 mg), both conducted under fasting conditions, and the food effect study (ALO 12.5 mg/MET XR 1000 mg) conducted under both fasting and fed conditions. Among enrolled participants, 46 of 50 completed the high‐dose bioequivalence study, 45 of 51 completed the low‐dose bioequivalence study, and 22 of 26 completed the food effect study. Plasma concentrations were analyzed using liquid chromatography‐tandem mass spectrometry. The geometric mean ratios of AUC last and C max for the FDC versus individual formulations were within the bioequivalence range (0.80‐1.25) for both ALO and MET XR. ALO's pharmacokinetics were unaffected by food, while MET XR exhibited a significant food effect, with AUC last increasing by a factor of 1.63 and T max delayed by 2 hours. Given these findings, the FDC should be administered with food, consistent with MET XR monotherapy recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminFastingUracilFood-Drug InteractionsPiperidinesHypoglycemic AgentsHumansMaleCross-Over StudiesTherapeutic EquivalencyAdultFemaleDelayed-Action PreparationsYoung AdultHealthy VolunteersArea Under CurveMiddle AgedDrug Combinations

Stichwörter der Autor:innen

alogliptindiabetes mellitusextended‐release formulationfixed‐dose combinationmetforminpharmacokinetics

Substanzen

MetforminalogliptinUracilDelayed-Action PreparationsPiperidinesHypoglycemic AgentsDrug Combinations

Autor:innen und Institutionen

  • Clinical Trials Center, Chungnam National University Hospital, Daejeon, Republic of Korea.
  • Department of Medical Science, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
  • Department of Pharmacology, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
  • Department of Family Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea.
  • Global Clinical Development Department, Celltrion Inc., Incheon, Republic of Korea.

Zitieren

APA

Song, J. H., Kim, J. H., Hong, J. H., Jung, J. G., Park, S. Y., & Sunwoo, J. (2025). Pharmacokinetics and Safety of a Fixed‐Dose Combination of Alogliptin and Extended‐Release Metformin Under Fasting and/or Fed Conditions in Healthy Adults. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1532

Vancouver

Song JH, Kim JH, Hong JH, Jung JG, Park SY, Sunwoo J. Pharmacokinetics and Safety of a Fixed‐Dose Combination of Alogliptin and Extended‐Release Metformin Under Fasting and/or Fed Conditions in Healthy Adults. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1532

BibTeX
@article{Song2025,
  author = {Song, Ji Hye and Kim, Jae Hoon and Hong, Jang Hee and Jung, Jin-Gyu and Park, Sun Young and Sunwoo, Jung},
  title = {Pharmacokinetics and Safety of a Fixed‐Dose Combination of Alogliptin and Extended‐Release Metformin Under Fasting and/or Fed Conditions in Healthy Adults},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1532}
}
Kostenlos starten →